UNIVEST FINANCIAL Corp Has $11.68 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• UNIVEST FINANCIAL Corp increased its stake in Regeneron Pharmaceuticals by 29.7%, holding shares valued at approximately $11.68 million.
• Analysts have mixed ratings on Regeneron, with a current consensus rating of "Moderate Buy" and a price target of $837.61.
• Regeneron reported Q1 earnings of $8.22 per share, missing estimates, with a year-over-year revenue decline of 3.7%.

UNIVEST FINANCIAL Corp grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 29.7% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 18,419 shares of the biopharmaceutical company's stock after acquiring an additional 4,217 shares during the quarter. UNIVEST FINANCIAL Corp's holdings in Regeneron Pharmaceuticals were worth $11,682,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of REGN. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the last quarter. Tompkins Financial Corp acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at about $32,000. Curat Global LLC bought a new position in Regeneron Pharmaceuticals in the first quarter valued at about $32,000. Finally, American National Bank & Trust bought a new position in Regeneron Pharmaceuticals in the first quarter valued at about $44,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Royal Bank Of Canada lowered shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research report on Friday, May 30th. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $837.61.

Regeneron Pharmaceuticals Stock Down 1.6%

Shares of NASDAQ:REGN opened at $545.46 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The business's 50-day moving average is $538.64 and its 200-day moving average is $604.99. The company has a market capitalization of $58.89 billion, a price-to-earnings ratio of 13.89, a P/E/G ratio of 2.08 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $9.55 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.